Heron Therapeutics, Inc. (NASDAQ:HRTX) has been given a $40.00 price objective by research analysts at Cowen and Company in a report released on Thursday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Cowen and Company’s price objective indicates a potential upside of 147.68% from the company’s current price.

Several other equities research analysts also recently commented on the company. Aegis reissued a “buy” rating and issued a $33.00 price objective on shares of Heron Therapeutics in a report on Tuesday, July 18th. Jefferies Group LLC reaffirmed a “buy” rating and set a $26.00 price target on shares of Heron Therapeutics in a report on Friday, July 14th. Zacks Investment Research raised Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Wednesday, July 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Heron Therapeutics in a report on Monday, June 26th. Finally, ValuEngine raised Heron Therapeutics from a “strong sell” rating to a “sell” rating in a report on Thursday, June 22nd. One research analyst has rated the stock with a sell rating and eleven have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $31.00.

Heron Therapeutics (NASDAQ:HRTX) traded down 1.22% during trading on Thursday, hitting $16.15. 315,386 shares of the stock were exchanged. The firm’s 50 day moving average price is $15.04 and its 200-day moving average price is $14.44. Heron Therapeutics has a 1-year low of $12.21 and a 1-year high of $24.00.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings data on Wednesday, May 10th. The biotechnology company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.94) by $0.06. The firm had revenue of $3.63 million during the quarter, compared to the consensus estimate of $1.96 million. Equities analysts expect that Heron Therapeutics will post ($3.72) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was posted by American Banking News and is the property of of American Banking News. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/08/06/heron-therapeutics-inc-hrtx-pt-set-at-40-00-by-cowen-and-company.html.

A number of large investors have recently made changes to their positions in HRTX. Legal & General Group Plc boosted its position in Heron Therapeutics by 26.6% in the second quarter. Legal & General Group Plc now owns 11,354 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 2,383 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Heron Therapeutics by 7.4% in the second quarter. Bank of New York Mellon Corp now owns 204,857 shares of the biotechnology company’s stock valued at $2,837,000 after buying an additional 14,086 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in Heron Therapeutics during the second quarter valued at $457,000. Rubric Capital Management LP boosted its position in Heron Therapeutics by 6.3% in the second quarter. Rubric Capital Management LP now owns 1,700,000 shares of the biotechnology company’s stock valued at $23,545,000 after buying an additional 100,000 shares during the last quarter. Finally, Rhumbline Advisers boosted its position in Heron Therapeutics by 14.1% in the second quarter. Rhumbline Advisers now owns 50,630 shares of the biotechnology company’s stock valued at $701,000 after buying an additional 6,249 shares during the last quarter.

About Heron Therapeutics

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.